GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
92.20
-2.14 (-2.27%)
At close: Mar 28, 2025, 4:00 PM
92.32
+0.12 (0.13%)
After-hours: Mar 28, 2025, 7:19 PM EDT
GeneDx Holdings Revenue
In the year 2024, GeneDx Holdings had annual revenue of $305.45M with 50.79% growth. GeneDx Holdings had revenue of $95.64M in the quarter ending December 31, 2024, with 66.57% growth.
Revenue (ttm)
$305.45M
Revenue Growth
+50.79%
P/S Ratio
8.12
Revenue / Employee
$305,450
Employees
1,000
Market Cap
2.59B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
WGS News
- 10 days ago - GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies - Business Wire
- 17 days ago - GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting - Business Wire
- 17 days ago - GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis - Business Wire
- 18 days ago - GeneDx Holdings: There Is Upside Potential, But Price Tag Is Rich - Seeking Alpha
- 26 days ago - GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication - Business Wire
- 4 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Connect - Accesswire
- 4 weeks ago - Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols - Business Wire